Pyxis Oncology Inc. (NASDAQ:PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).The update includes preliminary data from both the Phase 1 monotherapy study in second line (2L+) R/M HNSCC and the Phase 1/2 study evaluating MICVO in combination with Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab), in (first and second line) 1L/2L+ R/M HNSCC.The data reported below reflec ...